However, superior reductions in 6-month fasting insulin in the metformin arm, and in HOMA-IR in both M and MR arms, suggest potential additive benefit with the addition of insulin sensitizing medications in populations with documented insulin elevation and presumed risk for diabetes and metabolic syndrome. The gene discussed is INS; the disease is metabolic syndrome.